Colliding Challenges Part 2: An Analysis of SARS-CoV-2 Infection in Patients with Extrapulmonary Tuberculosis Versus SARS-CoV-2 Infection Alone DOI Creative Commons
Camil Mihuta, Adriana Socaci, Patricia Hogea

et al.

Medicina, Journal Year: 2024, Volume and Issue: 60(12), P. 2071 - 2071

Published: Dec. 16, 2024

Background and Objectives: Coinfection with SARS-CoV-2 extrapulmonary tuberculosis (extraPTB) presents unique clinical challenges due to dual inflammatory responses potential differences in patient profiles compared those infection alone. This study uniquely contributes the underexplored interaction between extraPTB SARS-CoV-2, focusing on systemic inflammation as a critical determinant of outcomes. Materials Methods: retrospective, cross-sectional included 123 patients aged 19–91 years, hospitalized at Victor Babeș Hospital Timișoara from March 2020 2022. We 23 coinfected 100 age-matched SARS-CoV-2-only patients. Clinical records were examined for demographic, clinical, laboratory data. Results: The group was younger, 65% under 40 presented significantly higher IL-6, PCT, transaminase levels. Coexisting COPD type 2 diabetes independent predictors coinfection. A SpO2 diagnosis positively associated coinfection likelihood (OR = 5.37), while CT scores indicated less pulmonary involvement Non-fatal outcomes more frequent (95.7% sensitivity), only one had fatal outcome versus 17 group. Low elevated IL-6 significant mortality, severe symptoms tripling fatality odds. Conclusions: is younger age, heightened inflammation, longer hospital stays but does not increase mortality risk These findings underscore importance monitoring markers developing tailored management strategies improve long-term care patients, especially resource-limited settings.

Language: Английский

Weathering the Storm: How Age and Biologics Influence the COVID-19 Cytokine Surge DOI Creative Commons

Corine Astroth,

Karishma S. Shah,

Sudhanshu Agrawal

et al.

Pathogens, Journal Year: 2025, Volume and Issue: 14(4), P. 346 - 346

Published: April 3, 2025

SARS-CoV-2, first identified in December 2019, caused a global pandemic, resulting over 6.8 million deaths by March 2023. The elderly, or individuals 65, accounted for the majority of COVID-19 deaths, with 81% fatalities US 2020 occurring this group. Beyond mortality, aging populations are also at higher risk long-term cardiovascular complications and acute respiratory distress syndrome (ARDS). Although these outcomes may be influenced comorbidities common age has been found to standalone factor severe infection. Therefore, investigating age-related factors is crucial protecting vulnerable Of particular interest cytokine storm phenomenon, an excessive inflammatory response that contributes symptoms, including ARDS damage. Elevated levels multiple cytokines cases COVID-19. We propose changes occur profiles as we contribute aberrant responses. This review specifically explored interleukin class IL-1, IL-6, IL-17, IL-23 considered potential biologics targeting alleviate both individuals.

Language: Английский

Citations

0
Immune Stimulation with Imiquimod to Best Face SARS-CoV-2 Infection and Prevent Long COVID DOI Open Access
Ursino Pacheco-García, Elvira Varela-López, Jeanet Serafín‐López

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(14), P. 7661 - 7661

Published: July 12, 2024

Through widespread immunization against SARS-CoV-2

Language: Английский

Citations

0
Predictors of 2-year mortality in geriatric patients hospitalized with COVID-19 in Türkiye: a retrospective cohort study DOI
Bahar Bektan Kanat, Gülru Ulugerger Avcı, Osman Faruk Bayramlar

et al.

Biomarkers in Medicine, Journal Year: 2024, Volume and Issue: 18(10-12), P. 555 - 565

Published: June 17, 2024

Methods: Demographic characteristics, clinical and laboratory data, thorax computed tomography (CT) images, second-year survival status, causes of death were analyzed.

Language: Английский

Citations

0
Colliding Challenges Part 2: An Analysis of SARS-CoV-2 Infection in Patients with Extrapulmonary Tuberculosis Versus SARS-CoV-2 Infection Alone DOI Creative Commons
Camil Mihuta, Adriana Socaci, Patricia Hogea

et al.

Medicina, Journal Year: 2024, Volume and Issue: 60(12), P. 2071 - 2071

Published: Dec. 16, 2024

Background and Objectives: Coinfection with SARS-CoV-2 extrapulmonary tuberculosis (extraPTB) presents unique clinical challenges due to dual inflammatory responses potential differences in patient profiles compared those infection alone. This study uniquely contributes the underexplored interaction between extraPTB SARS-CoV-2, focusing on systemic inflammation as a critical determinant of outcomes. Materials Methods: retrospective, cross-sectional included 123 patients aged 19–91 years, hospitalized at Victor Babeș Hospital Timișoara from March 2020 2022. We 23 coinfected 100 age-matched SARS-CoV-2-only patients. Clinical records were examined for demographic, clinical, laboratory data. Results: The group was younger, 65% under 40 presented significantly higher IL-6, PCT, transaminase levels. Coexisting COPD type 2 diabetes independent predictors coinfection. A SpO2 diagnosis positively associated coinfection likelihood (OR = 5.37), while CT scores indicated less pulmonary involvement Non-fatal outcomes more frequent (95.7% sensitivity), only one had fatal outcome versus 17 group. Low elevated IL-6 significant mortality, severe symptoms tripling fatality odds. Conclusions: is younger age, heightened inflammation, longer hospital stays but does not increase mortality risk These findings underscore importance monitoring markers developing tailored management strategies improve long-term care patients, especially resource-limited settings.

Language: Английский

Citations

0